A Phase 3 interventional study of Ubrogepant and Placebo-matching Ubrogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 109 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one has the largest enrollment, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 4th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,686 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 2nd largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2016, is one of 30 in phase 3, and was the 19th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant
1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant
1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Drug: Placebo-matching Ubrogepant
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
Pain freedom was defined as a reduction in headache pain severity from moderate/severe at baseline to no pain at 2 hours after the initial dose of investigational product. Participants were provided with electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.
Time frame: Baseline (Predose) to 2 hours after initial dose
Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms assessed.
Time frame: Baseline (Predose) to 2 hours after initial dose
Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose
Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.
Time frame: Baseline (Predose) to 2 hours after initial dose
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose
Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain relief from 2 to 24 hours after initial dose.
Time frame: 2 to 24 hours after initial dose
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose
Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain freedom from 2 to 24 hours after initial dose.
Time frame: 2 to 24 hours after initial dose
Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose
Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.
Time frame: 2 hours after initial dose
Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose
Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.
Time frame: 2 hours after initial dose
Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose
Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.
Time frame: 2 hours after initial dose
| Milestone | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Started | 563 | 561 | 562 |
| Safety population: received study drug | 499 | 478 | 488 |
| Completed | 493 | 474 | 487 |
| Not completed | 70 | 87 | 75 |
| Withdrew: Adverse event | 1 | 1 | 2 |
| Withdrew: Withdrawal of consent | 7 | 9 | 8 |
| Withdrew: Lost to follow-up | 17 | 20 | 20 |
| Withdrew: Lack of qualifying event | 42 | 55 | 42 |
| Withdrew: Protocol violation | 3 | 2 | 3 |
| Milestone | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Started | 493 | 474 | 487 |
| Completed | 482 | 459 | 473 |
| Not completed | 11 | 15 | 14 |
| Withdrew: Withdrawal of consent | 1 | 8 | 6 |
| Withdrew: Lost to follow-up | 10 | 5 | 7 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
Pain freedom was defined as a reduction in headache pain severity from moderate/severe at baseline to no pain at 2 hours after the initial dose of investigational product. Participants were provided with electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose | 14.3 | 20.7 | 21.8 |
The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms assessed.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose | 27.4 | 34.1 | 38.9 |
Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose | 48.2 | 60.5 | 62.7 |
Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain relief from 2 to 24 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose | 21.0 | 32.5 | 36.7 |
Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with assessment of determinable sustained pain freedom from 2 to 24 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose | 8.2 | 12.7 | 14.4 |
Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose | 35.5 | 39.3 | 43.8 |
Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose | 46.3 | 53.6 | 54.1 |
Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.
| percentage of participants | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose | 70.0 | 70.6 | 71.3 |
Collected over From first dose through 30 days after the last dose of study drug (approximately 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/499 (0%) | 0/499 (0%) | 0/499 (0%) |
| Ubrogepant 25 mg | 0/478 (0%) | 1/478 (0.2%) | 0/478 (0%) |
| Ubrogepant 50 mg | 0/488 (0%) | 0/488 (0%) | 0/488 (0%) |
| Event | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg |
|---|---|---|---|
| Ligament sprainInjury, poisoning and procedural complications | 0/499 | 1/478 | 0/488 |
| Loss of consciousnessNervous system disorders | 0/499 | 1/478 | 0/488 |
| Renal haematomaRenal and urinary disorders | 0/499 | 1/478 | 0/488 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/499 | 1/478 | 0/488 |
| Splenic ruptureInjury, poisoning and procedural complications | 0/499 | 1/478 | 0/488 |
| SyncopeNervous system disorders | 0/499 | 1/478 | 0/488 |
| Traumatic renal injuryInjury, poisoning and procedural complications | 0/499 | 1/478 | 0/488 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg | Total |
|---|---|---|---|---|
| Mean | 41.5 ± 12.2 | 41.6 ± 12.3 | 41.0 ± 12.4 | 41.4 ± 12.3 |
| Sex: Female, Male(Participants) | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg | Total |
|---|---|---|---|---|
| Female | 494 | 501 | 497 | 1492 |
| Male | 69 | 60 | 65 | 194 |
| Race/Ethnicity, Customized(Participants) | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg | Total |
|---|---|---|---|---|
| White | 449 | 467 | 456 | 1372 |
| Black or African American | 94 | 82 | 93 | 269 |
| Asian | 8 | 6 | 5 | 19 |
| American Indian or Alaska Native | 4 | 1 | 4 | 9 |
| Native Hawaiian/Other Pacific Islander | 1 | 1 | 1 | 3 |
| Multiple | 7 | 4 | 3 | 14 |
| Race/Ethnicity, Customized(Participants) | Placebo | Ubrogepant 25 mg | Ubrogepant 50 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 116 | 129 | 125 | 370 |
| Not Hispanic or Latino | 447 | 432 | 437 | 1316 |
Showing the first 100 of 109 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Jan 2018, 16 months.
Results were first posted in Jan 2019, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant